Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (19)

2024

  1. Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure

    ESC Heart Failure, Vol. 11, Núm. 3, pp. 1767-1776

  2. Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease

    Archivos de Bronconeumologia, Vol. 60, Núm. 4, pp. 226-237

  3. Obesity and cardiovascular and renal disease. Consensus document of the Preventive Cardiology, Clinical Cardiology, and Heart Failure Associations of the Spanish Society of Cardiology

    REC: CardioClinics

  4. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry

    Revista espanola de cardiologia (English ed.), Vol. 77, Núm. 1, pp. 50-59

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  2. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  3. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  4. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  5. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry

    Revista Espanola de Cardiologia

  6. Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry

    Current Heart Failure Reports, Vol. 20, Núm. 3, pp. 157-167

  7. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

    Journal of Cardiac Failure, Vol. 29, Núm. 5, pp. 849-854

2022

  1. Key factors for optimal care models for heart failure. An integrative and multidisciplinary approach

    REC: CardioClinics, Vol. 57, Núm. 1, pp. 24-38

  2. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  3. Recommendations to develop Care Models for patients with Heart Failure (MAIC Project) from macromanagement

    Journal of Healthcare Quality Research, Vol. 37, Núm. 2, pp. 100-109

  4. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

2020

  1. Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS)

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 4448-4457

2018

  1. Genetic Etiology for Alcohol-Induced Cardiac Toxicity

    Journal of the American College of Cardiology, Vol. 71, Núm. 20, pp. 2293-2302

2017

  1. Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: The AGTP II trial

    BMJ Open, Vol. 7, Núm. 8